The prevention of pneumococcal disease by vaccines: promises and challenges.
This article reviews the epidemiology of pneumococcal disease and the current data on pneumococcal vaccine efficacy, discusses promising new data regarding development of new protein-conjugate pneumococcal vaccines, and addresses controversies surrounding the widespread population use of these vaccines. Armed with these data, physicians, nurses, third party payers, and health care systems should develop systems and eliminate unintentional barriers so as to achieve widespread use of these life-saving vaccines. As history has demonstrated to us, control of pneumococcal disease is highly unlikely to occur from heavy investments in newer and ever more expensive antibiotics, as opposed to better methods of preventing disease through the rational and widespread population use of vaccines.
Poland
G A
GA
Clinical Pharmacology Unit, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D005544:Forecasting; D017408:Guidelines as Topic; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D012449:Safety; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate